ESMO 2025: SunRISe-4 Results and Highlights Across MIBC and mUCSent on 21 October 2025
ESMO 2025: Trial Results from ENZARAD - PRESTO - EMBARK - CAPItello-281 - PSMAAddition Sent on 21 October 2025
Advances in Imaging Based Theranostics from ESMO 2025 Sent on 19 October 2025
ESMO 2025: Renal Cell Carcinoma Focused on New Data Supporting Evolving Treatment Strategies Sent on 19 October 2025
ESMO 2025: Enfortumab Vedotin + Pembrolizumab Drives Survival Gains in MIBCSent on 19 October 2025
ESMO 2025: Radioligand and Combination Strategies in Prostate CancerSent on 18 October 2025
ESMO 2025 Trials Shaping What’s Next in Renal & Urothelial CancerSent on 18 October 2025
ESMO 2025: Advancing Care in Metastatic Prostate Cancer and BeyondSent on 18 October 2025
European Society for Medical Oncology (ESMO) 2025: Defining New Standards in Urothelial Cancer CareSent on 17 October 2025
ESMO 2023 Management of High-Risk Localized Prostate Cancer & Evolving Data on Treatments and Toxicities in Genitourinary CancersSent on 26 October 2023
ESMO 2023 A New Standard of Care in the First-Line Treatment of Urothelial CarcinomaSent on 25 October 2023
ESMO 2023 Breaking Data: PSMAfore Study Demonstrates Practice-Changing Results for Advanced Prostate Cancer Treatment Sent on 23 October 2023
ESMO 2023 Breaking Data in mCRPC: Three-year Update and Final Analysis MAGNITUDE & ProBio, a Biomarker-Driven Platform TrialSent on 22 October 2023
ESMO 2023 Organ Preservation Across Stages of Bladder Cancer and Latest Data and Discussion on LITESPARK Trials in Renal Cancer Sent on 22 October 2023
ESMO 2023 Latest Breakthroughs in the Treatment of Advanced Urothelial CancerSent on 21 October 2023
ESMO 2023 Highlights: Optimizing Survival in Advanced Renal Cancer and Noteworthy Data on The Timing of Radiotherapy After Radical Prostatectomy Randomized Controlled Trial Sent on 21 October 2023
Join UroToday for Access to ESMO 2023 Congress Highlights Starting Friday, October 20thSent on 17 October 2023
ESMO 2022 Multidisciplinary Updates in Genitourinary Tumors and Biomarkers in Urinary CancersSent on 15 September 2022
ESMO 2022 PSMA Biology, Diagnostics, and TreatmentSent on 14 September 2022
Treatment Management in Prostate Cancer ESMO 2022 HighlightsSent on 13 September 2022
ESMO 2022 Presidential Symposium III in Kidney Cancer Results From the COSMIC-313, RADICALS-HD Trial and Orals in Bladder CancerSent on 12 September 2022
ESMO 2022 Presidential Symposium II in Kidney Cancer Results From the Phase 3 CheckMate 914 Trial and Mini Orals in Bladder CancerSent on 12 September 2022
ESMO 2022 Prostate Cancer Mini Oral Session: Quality of Life in the ARASENS Study, The CABASTY Randomized Phase III Trial, and Preliminary Phase 2 Results of the CYPIDES StudySent on 11 September 2022
ESMO 2022 Late Breaking Abstracts in Prostate Cancer - Overall Survival Results From the STAMPEDE Protocol and PRESTO AFT-19 in High-Risk Biochemically Relapsed Prostate CancerSent on 11 September 2022
ESMO 2022 Highlights - Biomarkers for Advanced Urothelial Carcinoma and Do the Results of the Perioperative Renal Cancer Trials Make SenseSent on 10 September 2022
Display #
Results 1 - 25 out of 25